STOCK TITAN

Motus GI Scheduled to Present at Investor Conferences in September 2020

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

FORT LAUDERDALE, Fla., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to be presenting at the following upcoming virtual investor conferences:

  • H.C. Wainwright 22nd Annual Global Investment Conference – Presenting on Tuesday, September 15, 2020 at 2:00 p.m. Eastern Time. The presentation will be accessible via a live and archived webcast at https://wsw.com/webcast/hcw7/mgh/1464380 or the Events page on the Company’s website, www.motusgi.com

  • Oppenheimer Fall Healthcare Life Sciences & MedTech Summit – Presenting on Tuesday, September 22, 2020 at 3:20 p.m. Eastern Time. The presentation will be accessible via a live and archived webcast at https://wsw.com/webcast/oppenheimer5/mgh/2474460 or the Events page on the Company’s website, www.motusgi.com

About Motus GI

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.

For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.

Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989
bob@lifesciadvisors.com


MOTUS GI HOLDINGS INC

OTC:MOTS

MOTS Rankings

MOTS Latest News

MOTS Stock Data

435.11k
4.97M
1.12%
4.71%
0.45%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
FT. LAUDERDALE

About MOTS

motus gi holdings, inc. (nasdaq: mots) is a medical technology company based in the u.s., with subsidiaries in the u.s. and israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. the company is focused on the development and commercialization of the pure-vu® system, designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. the pure-vu® system is a 510(k) u.s. food and drug administration cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. the device integrates with standard colonoscopes to enable cleaning during the procedure while preserving standard procedural workflow and techniques. the pure-vu® system has received ce mark approval in europe.